Shiber A, Reuveni H, Elhayany A, Ben-Zion I Z
Psychiatric Dept., Soroka Medical Center, Beer Sheba.
Harefuah. 1998 Dec 15;135(12):596-8, 654.
Fluoxetine is now a well-known and often-used specific serotonin reuptake inhibitor (SSRI) and antidepressant. It has a very long active half-life, from 2-16 days. Our hypothesis was that sufficient therapeutic effectiveness would be achieved by prescribing the drug less frequently than once a day. To establish whether there is a difference between fluoxetine given daily or every 3 days, we assigned 25 outpatients with mild to moderate, acute major depressions (DSM-IV) to receive fluoxetine (20 mg), either each day or every 3 days. The study was open-labelled, using for assessment the HAM-D, GHQ-28 side-effect checklist and clinical judgment questionnaires. Follow-up lasted 6 months. Results indicated no differences in the clinical outcomes, except for slightly fewer side-effects in the study group. Although the open label design limits drawing definitive conclusions, our preliminary results provide more information, and support our hypothesis that low-dosage fluoxetine is beneficial. However, more comprehensive, double-blind studies are necessary to confirm our preliminary results.
氟西汀是一种广为人知且常用的特异性5-羟色胺再摄取抑制剂（SSRI）及抗抑郁药。其活性半衰期很长，为2至16天。我们的假设是，通过低于每日一次的给药频率能够实现足够的治疗效果。为确定每日给药与每3日给药的氟西汀之间是否存在差异，我们将25例患有轻度至中度急性重度抑郁症（DSM-IV）的门诊患者分配为每日或每3日接受氟西汀（20毫克）治疗。该研究为开放性标签，使用汉密尔顿抑郁量表（HAM-D）、一般健康问卷-28项（GHQ-28）副作用清单及临床判断问卷进行评估。随访持续6个月。结果表明，除研究组的副作用略少外，临床结局并无差异。尽管开放性标签设计限制了得出明确结论，但我们的初步结果提供了更多信息，并支持我们关于低剂量氟西汀有益的假设。然而，需要更全面的双盲研究来证实我们的初步结果。
